Biological equivalent dose studies for dose escalation in the stereotactic synchrotron radiation therapy clinical trials.
Synchrotron radiation is an innovative tool for the treatment of brain tumors. In the stereotactic synchrotron radiation therapy (SSRT) technique a radiation dose enhancement specific to the tumor is obtained. The tumor is loaded with a high atomic number (Z) element and it is irradiated in stereotactic conditions from several entrance angles. The aim of this work was to assess dosimetric properties of the SSRT for preparing clinical trials at the European Synchrotron Radiation Facility (ESRF). To estimate the possible risks, the doses received by the tumor and healthy tissues in the future clinical conditions have been calculated by using Monte Carlo simulations (PENELOPE code). The dose enhancement factors have been determined for different iodine concentrations in the tumor, several tumor positions, tumor sizes, and different beam sizes. A scheme for the dose escalation in the various phases of the clinical trials has been proposed. The biological equivalent doses and the normalized total doses received by the skull have been calculated in order to assure that the tolerance values are not reached.
Prezado
Y
Y
ID17 Biomedical Beamline, European Synchrotron Radiation Facility (ESRF), 6 rue Jules Horowitz, BP 220, 38043 Grenoble Cedex, France. prezado@esrf.fr
Fois
G
G
Edouard
M
M
Nemoz
C
C
Renier
M
M
Requardt
H
H
Estève
F
F
Adam
J F
JF
Elleaume
H
H
Bravin
A
A
D055592:Biophysical Phenomena; D001932:Brain Neoplasms / Q000532:radiotherapy*; D002986:Clinical Trials as Topic; D006801:Humans; D009010:Monte Carlo Method; D019047:Phantoms, Imaging; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted; D013238:Stereotaxic Techniques; D017356:Synchrotrons / Q000706:statistics & numerical data